Molecular basis for mid-region amyloid-β capture by leading Alzheimer's disease immunotherapies.
about
High-affinity Anticalins with aggregation-blocking activity directed against the Alzheimer β-amyloid peptide.Structure of Crenezumab Complex with Aβ Shows Loss of β-Hairpin.Ex vivo 18O-labeling mass spectrometry identifies a peripheral amyloid β clearance pathwayProtein misfolding in neurodegenerative diseases: implications and strategies.Conformational selection in amyloid-based immunotherapy: Survey of crystal structures of antibody-amyloid complexes.Amyloid beta: structure, biology and structure-based therapeutic development.Erratum to: Do anti-amyloid beta protein antibody cross reactivities confound Alzheimer disease research?Fibrillation-prone conformations of the amyloid-β-42 peptide at the gold/water interface.Anti-Amyloid-β Monoclonal Antibodies for Alzheimer's Disease: Pitfalls and Promise.Mechanisms of recognition of amyloid-β (Aβ) monomer, oligomer, and fibril by homologous antibodies.Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β.Abeta targets of the biosimilar antibodies of Bapineuzumab, Crenezumab, Solanezumab in comparison to an antibody against N‑truncated Abeta in sporadic Alzheimer disease cases and mouse models.MX2: a high-flux undulator microfocus beamline serving both the chemical and macromolecular crystallography communities at the Australian Synchrotron.Antibody Engineering for Optimized Immunotherapy in Alzheimer's Disease.Molecular Docking and Dynamic Simulation of AZD3293 and Solanezumab Effects Against BACE1 to Treat Alzheimer's Disease.Computational Analysis for the Rational Design of Anti-Amyloid Beta (Aβ) AntibodiesThe interaction with gold suppresses fiber-like conformations of the amyloid β (16–22) peptideThe Amyloid-β Peptide in Amyloid Formation Processes: Interactions with Blood Proteins and Naturally Occurring Metal Ions
P2860
Q35974386-A7D18FBC-92B0-4012-8AA5-44CB62E3A489Q37519267-BB209AA2-F724-4756-8F1B-91D015B3CFCCQ37652424-3E4F0FF8-B951-4122-9972-BFDE0DB58147Q37697832-0A9E65C0-248B-4BA4-BB98-2E55E1EB4BF7Q38856199-A64752E0-A5DD-4BDA-A6FD-EE03749722D1Q39437881-C569B4D4-2448-413B-9359-2A735B768A02Q42317412-B90AE5DC-B64A-43DD-8419-40527FB38B09Q45968145-D3296FED-EFA1-48A9-9DED-695F39BE711BQ46297382-E35823EA-A3B5-451C-A8DD-5C3AC80CD2F7Q47565290-DBDC7BD6-E259-4393-A641-FE0841856662Q52568535-6CE31D4F-23F0-4160-829D-6022B3B7E8FFQ53311356-B79DC75F-6067-4C12-A1D2-6DFD71E77073Q54224083-474BE9CB-909A-41A0-8B92-9AC1A4264775Q54982684-A25A7EE8-7059-458C-977A-909241876B8EQ55346213-0D3AD4B5-7849-41B4-A2A3-ACC1DC1E0B72Q57903229-B8887627-DD4F-42A3-91DF-B393BD8C621FQ57952194-AA67738C-ED08-4F23-AD1B-3531162F9E20Q58486506-7422F838-D024-4F87-BB11-1E1CD58DB5A8
P2860
Molecular basis for mid-region amyloid-β capture by leading Alzheimer's disease immunotherapies.
description
2015 nî lūn-bûn
@nan
2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Molecular basis for mid-region ...... mer's disease immunotherapies.
@ast
Molecular basis for mid-region ...... mer's disease immunotherapies.
@en
Molecular basis for mid-region ...... mer's disease immunotherapies.
@nl
type
label
Molecular basis for mid-region ...... mer's disease immunotherapies.
@ast
Molecular basis for mid-region ...... mer's disease immunotherapies.
@en
Molecular basis for mid-region ...... mer's disease immunotherapies.
@nl
prefLabel
Molecular basis for mid-region ...... mer's disease immunotherapies.
@ast
Molecular basis for mid-region ...... mer's disease immunotherapies.
@en
Molecular basis for mid-region ...... mer's disease immunotherapies.
@nl
P2093
P2860
P356
P1433
P1476
Molecular basis for mid-region ...... mer's disease immunotherapies.
@en
P2093
Gabriela A N Crespi
Luke A Miles
Stefan J Hermans
P2860
P2888
P356
10.1038/SREP09649
P407
P577
2015-04-16T00:00:00Z
P5875
P6179
1042086198